Protox LogoVancouver, British Columbia, October 18, 2007 – Protox Therapeutics Inc. (TSX-V:PRX), a leader in advancing novel, targeted protein toxin therapeutics for the treatment of cancer and other proliferative diseases, today announced that the U.S. Patent and Trademark Office has issued U.S. Patent 7,282,476 covering the composition of PRX302, the Company’s lead drug candidate from its PORxinTM technology platform, and its use for the treatment of prostate cancer. Additional claims were issued which protect other modified proaerolysin variants targeting prostate cancer. The patent was issued to the University of Victoria Innovation and Development Corporation and Johns Hopkins University and is licensed to Protox on an exclusive worldwide basis. "The issuance of Protox’s first U.S. patent provides key patent protection for PRX302 and is an important step in strengthening our PORxin intellectual property portfolio,” said Dr. Fahar Merchant, President and Chief Executive Officer of Protox. “We continue to file and prosecute additional patent applications in the U.S., Canada and globally to build and protect all of our valuable discoveries.”